Embera NeuroTherapeutics, Inc. is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brain functions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.

EMB-001 has successfully demonstrated clinical activity in a pilot clinical study in cocaine-dependent subjects. In addition, efficacy against cocaine, nicotine and methamphetamine dependence has been shown in preclinical models of addiction.

Financials

People